The primary objective of this study is to determine whether combined treatment of exercise and NR imposes greater improvements in skeletal muscle mitochondrial metabolism in older humans compared to exercise treatment alone. The secondary objective…
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
veroudering, energiemetabolisme, type 2 diabetes
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary study endpoints is ex vivo skeletal muscle mitochondrial function
measured via high-resolution respirometry.
Secondary outcome
The secondary study outcome is sleeping metabolic rate measured during an
overnight stay in the respiration chamber.
Explorative objectives are muscle (NAD) metabolites, energy metabolism and
physical performance.
Background summary
The number of age-related chronic diseases (like obesity, type 2 diabetes and
cardiovascular diseases) is increasing rapidly worldwide, reaching pandemic
proportions. These age-related chronic diseases are associated with metabolic
disturbances and mitochondrial dysfunction in humans. Nicotinamide adenosine
dinucleotide (NAD) levels play an important role in energy metabolism and
mitochondrial functioning and indeed it has been shown that high concentrations
of NAD+ as well as a high NAD+/NADH ratio are strongly associated with
metabolic and mitochondrial health. In contrast, decreased NAD+ bioavailability
is reported in both ageing and obese humans as well as in diabetic mice. These
findings fuelled the idea of influencing NAD+ bioavailability in order to
improve metabolic disturbances and mitochondrial dysfunction in humans.
Supplementation with nicotinamide riboside (NR), a naturally occurring form of
vitamin B3, may provide a way to boost cellular NAD+ levels. However, in
contrast to animal studies, NR supplementation in humans has so far been
unsuccesful in improving skeletal muscle mitochondrial function, exercise
capacity or insulin sensitivity. Recently, it has been suggested that a
situation where NAD+ levels become limited, is needed for NR supplementation to
exert beneficial health effects. This situation could be achieved by combining
exercise and NR supplementation. However, studies combining NR and exercise are
lacking, which is why we would like to perform such a study here.
Study objective
The primary objective of this study is to determine whether combined treatment
of exercise and NR imposes greater improvements in skeletal muscle
mitochondrial metabolism in older humans compared to exercise treatment alone.
The secondary objective of this study is to determine whether combined
treatment of exercise and NR imposes greater improvements in sleeping metabolic
rate in older humans compared to exercise treatment alone. As explorative
objectives, we will examine whether combined treatment with exercise and NR
imposes greater improvements in muscle (NAD) metabolites, energy metabolism and
physical performance.
Study design
The present study is a randomized, double-blinded, placebo-controlled double
arm longitudinal intervention study in a pre and post design.
Intervention
Participants will be asked to take two pills of NR (250mg/pill), or placebo,
twice daily (two with breakfast and two with diner, a total of 4 pills/day;
1000mg/day), for 40 days. During days 17-38 of the NR intervention,
participants will perform a 3-weeks supervised exercise training program with
four ~30 min exercise sessions per week (two endurance session on a bike at
70%Wmax and two high intensity interval (HIIT) sessions. Participants will be
randomly assigned to the placebo + exercise or NR + exercise arm. To assess the
outcomes, participants will undergo three test days before the start of the NR
supplementation and repeat these three test days at the end (day 38-40) of NR
supplementation.
Study burden and risks
Before starting the intervention (exercise training + placebo or exercise
training + NR), participants will visit the University 4 times for the
screening and pre-intervention test days (total time investment 20.5 hours,
divided over 4 days). During the intervention period, subjects will visit the
University 4 times per week for 3 weeks to receive supervised exercise training
(total time investment 6 hours; 2 hours/week). The last exercise session
(training session 12) and post-intervention test day 1 will be combined on day
38. Post-intervention test day 2 will be performed on day 39-40. The time
investment for the post-intervention test days includes 20.5 hours. The main
burden of this study is the large time investment for the exercise training
period (3 weeks, 4 times/week). Moreover, the pre- and post-training test days
comprise several non-invasive and invasive measurements. The used techniques
are safe, but the muscle biopsies can cause some discomfort and may result in a
local bruise or hematoma. Likewise, blood sampling can cause a local hematoma.
The risk of infection and/or prolonged bleeding is very low due to
state-of-the-art techniques and sterility measures. Measurements performed
during the time course of the study can potentially lead to unexpected medical
findings. Subjects will be informed about such a finding and possible advised
to contact a doctor about this. If a subject does not want to be informed about
incidental findings, participation in this study is not possible.
P. Debyelaan 25
Maastricht 6229 HX
NL
P. Debyelaan 25
Maastricht 6229 HX
NL
Listed location countries
Age
Inclusion criteria
• Participants are able to provide signed and dated written informed consent
prior to any study specific procedures
• Aged >= 65 and <= 80 years
• Body mass index (BMI) 25 - 35 kg/m2
• Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)
• No signs of active cardiovascular disease, liver or kidney malfunction
Exclusion criteria
• Type 2 diabetes
• Patients with congestive heart failure and and/or severe renal and or liver
insufficiency
• Uncontrolled hypertension
• Any contra-indication for MRI scanning
• Alcohol consumption of >3 servings per day for man and >2 servings per day
for woman
• Smoking
• Unstable body weight (weight gain or loss > 5kg in the last 3 months)
• Engagement in structured exercise activities > 2 hours a week
• Previous enrolment in a clinical study with an investigational product during
the last 3 months or as judged by the Investigator which would possibly hamper
our study results
• Medication use known to hamper subject*s safety during the study procedures
• Subjects who do not want to be informed about unexpected medical findings
• Subjects who intend to donate blood during the intervention or subjects who
have donated blood less than three months before the start of the study
• Use of food supplements containing NR or Resveratrol (similar working
mechanisms)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT04907110 |
CCMO | NL77756.068.21 |